Multiple Sclerosis

Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is an antibody-mediated inflammatory condition of the central nervous system (CNS) with overlapping clinical features which can mimic other neuroinflammatory conditions such as multiple …

There is increasing evidence of metabolic perturbations in multiple sclerosis (MS) patients, and insulin is an important parameter that has controversial effects on neurological disease. Therefore, this systematic review and meta-analysis study …

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system (CNS) characterized by the accumulation of inflammatory cells and cytokines at the sites of demyelination and plaque formation [ 1 ]. Ocrelizumab …

Multiple sclerosis (MS) is an autoimmune-mediated disease of the central nervous system characterized by inflammation, demyelination and chronic progressive neurodegeneration. Among its broad and unpredictable range of clinical symptoms, cognitive …

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently defined demyelinating disorder affecting the central nervous system, manifesting across all age groups with a broad clinical spectrum encompassing monophasic and …

Disability accrual in patients with multiple sclerosis (pwMS) can derive from two main mechanisms, relapse-associated worsening (RAW) on the one hand, and progression independent from relapse activity (PIRA) on the other [ 1 , 2 ]. RAW has been …

Multiple sclerosis (MS) is a demyelinating inflammatory autoimmune disorder characterized by continuous and diffuse changes in the white and grey matter, and damage to axons [ 1 ]. Despite recent advancements in disease-modifying therapies …

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that is approved for the treatment of relapsing and primary progressive multiple sclerosis (MS), and acts primarily through the depletion of B cells [ 1 ]. Ocrelizumab is administrated …